

Remarks/Arguments:

Claims 1-11 and 15-18 were pending in the instant application prior to the instant amendment. Applicants have hereby amended claims 1-10, canceled claims 17-18 and added new claim 19 so that claims 1-11, 15-16 and 19 are now pending in the application.

It is noted that the Information Disclosure Statement filed 3/22/2007 has been made of record. Applicants respectfully request the examiner initial each of the references to indicate the examiner has considered them.

Claims 1-11 and 15-18 stand rejected under 35 USC §112, second paragraph, as being indefinite. The rejection of claims 1-3 and 10 based on the language "and salts" is respectfully submitted to have been overcome by amending "and salts" to "or ... salts" as suggested by the examiner. The suggestion to replace "and salts or solvates thereof" (emphasis added) is not understood since "or solvates" does not appear in any of the claims.

The rejection of claims 1-3 and 10 based on the recitation "of salts" as being indefinite because the compounds have a pharmaceutical utility is believed to be in error however, in order to expedite prosecution, applicants have amended claims 1-3 and 10 to replace "salts" with "pharmaceutically-acceptable salts". Applicants reserve the right to prosecute the canceled subject matter in a timely filed continuation application.

The examiner rejected claims 1-11 and 15-18 under 35 USC §112, second paragraph, but only gave specific rejections for claims 1-3 and 10. Applicants believe they have overcome the outstanding rejections under 35 USC §112, second paragraph, but if they are mistaken, clarification is respectfully requested.

The rejection of claims 17-and 18 under 35 USC §112, first paragraph, has been overcome by canceling those claims. New claim 19 has been added to cover the use of the compounds of the instant invention in treating breast cancer. The examiner has indicated that the specification is "enabling for treating breast tumor" (see page 3 of the Office Action). Support for new claim 19 can be found in the specification, e.g. page 87, lines 3-5 and page 88, lines 15-20.

Claims 4-10 have been amended to add "or a pharmaceutically-acceptable salt thereof". Support for these amendments can be found, e.g. in original claim 1 taken together with original claims 4-10.

It is respectfully submitted no new matter has been added by the instant amendment.

The above amendments have been made without prejudice to Applicants right to prosecute any canceled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 101346-1P US.

Respectfully submitted,

/Carol A. Loeschorn/

Name: Carol A. Loeschorn
Dated: 23 December 2008
Reg. No.: 35,590
Phone No.: 781-839-4002

Global Intellectual Property, Patents
AstraZeneca R&D Boston
35 Gatehouse Drive
Waltham,
MA 02451